NIHR University College London Hospitals Biomedical Research Centre - - PowerPoint PPT Presentation

18/03/2013

NIHR University College London Hospitals Biomedical Research Centre Report to UCLH Board

Bryan Williams MD FRCP FESC FAHA

Professor of Medicine and BRC Director

NIHR University College London Hospitals Biomedical Research Centre

The NIHR UCLH BRC

• Renewed funding circa £100M for 5 years in April 2012;
• Required a “refresh” of research strategy;
• 17 themes reduced to 4 major research Programmes;
• Cancer,
• Neuroscience,
• 3Is (Infection, Immunity, Inflammation),
• Cardiometabolic;
• New BRC Director;
• 4 Programme Directors & Education/Training PD;
• Operations manager for each programme;
• BRC COO, also COO for R&D functions.

NIHR University College London Hospitals Biomedical Research Centre

Changing face of the BRC

• New BRC
• Focussed on Experimental Medicine
• Early phase human studies
• CRF-based / Detailed clinical evaluation

Context for Change

• NHS “Innovation for Health and Wealth”

Agenda;

• Major Government investment in UK

Bioscience;

• Key emphasis on leverage and wealth creation;
• Industrial engagement – Pharma, MedTech,

Biotech and SMEs;

• Enterprise and Entrepreneurship from within;
• Inward investment – Export Innovation
• Innovation in Health Care; the “value

proposition”

NIHR University College London Hospitals Biomedical Research Centre

NIHR University College London Hospitals Biomedical Research Centre

Experimental Medicine and the Translational Pathway

NIHR University College London Hospitals Biomedical Research Centre

UCL/UCLH

UCLH BRC Clinical Trials

UCLP

UCLH Innovation Office

UCLB / TRO / UCL Enterprise

Reverse Translation

Creating Health and Wealth

Accelerate translation

Industrial Collaboration Sir Francis Crick Institute Cross BRC/BRU Collaboration Pan-London Collaboration CHAPTER eHealth

Change Process..

• Realignment of UCLH BRC funding towards

Experimental Medicine;

Consultant PA’s, Non Consultant Staff, NHS Research Support Costs

• Criteria for BRC support;

Research in the domain of experimental medicine Research of high quality – REF returnable Leverage of BRC support – “blue chip funding”, matched funding (faculty, NHS, industry, research councils, research charities, etc.) Potential for Impact on Health and Wealth

NIHR University College London Hospitals Biomedical Research Centre

BRC Budget Realignment

NIHR University College London Hospitals Biomedical Research Centre

“To build Capacity and deliver a step-change in World Class Experimental Medicine Research”

The BRC budget review process should realign

£20 million

for Experimental Medicine (~£5M per annum)

BRC Budget Realignment

NIHR University College London Hospitals Biomedical Research Centre

In addition to Existing Substantial BRC funding for research and infrastructure that continues to be embedded in UCLH

What will success look like?

Expand and Accelerate

• Expansion of experimental medicine capability, capacity and delivery;

Culture and Entrepreneurship

• A vibrant culture of innovation, enterprise and entrepreneurship “hard-

wired” into everything we do…and recognised and rewarded; Partnership and Industry

• Attracting major inward investment by industry – Pharma, Med-tech,

Cell therapies, Diagnostics, Imaging – real partnerships not simply transactional; Health and Wealth Creation

• Improved health care efficiency and patient outcomes from fast-tracked

innovation – wealth creation

NIHR University College London Hospitals Biomedical Research Centre

BRC National Comparisons

UCLH

NIHR Analysis of Annual Reports 2011/12

The most early phase human trials

Implications for UCLH

• BRC funding is now robustly performance

managed against delivery of the health and wealth agenda;

• BRC budget needs to be strategically deployed;
• Cost pressure (CSR) – need to be the best;
• Failure to deliver would be catastrophic for UCLH

On the Horizon…..

• Later Phase Clinical Trials – National

Reconfiguration;

• National NIHR Bioresource and Health

Informatics initiatives – eHealth agenda;

• Integrating and leveraging UCLP as gateway

to scale.